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Abstract 
 
Historically, the FDA has interpreted the requirement that a drug must be “safe” to mean that the benefits of a drug 
outweigh its risks. The determination was made on a “categorical” basis, where the totality of risks was weighted against 
the totality of benefits when considered for the purposes outlined in the drug product’s labeling. If a drug did not meet this 
criterion, it was not approved or its label was rewritten to narrow the conditions for use. This logic was endemic in the 
FDA for most of the 20th century. On average, two to four drugs over each 5-year period were withdrawn from the 
marketplace after post-marketing surveillance data uncovered new risks. Similarly, on occasion, the FDA would require 
some special “tool” or intervention to improve a product’s safety profile.Harm associated with medication remains the 
second most common type of incident in hospitals, as reported by the Clinical Excellence Commission. Health services 
actively review medication safety.The vast majority of medication errors result in no injury.  A minor injury may result, 
for example, in a patient needing an increased level of monitoring.  Even if incidents result in minor injury, managers and 
staff still take any errors very seriously, reviewing the actions around the incident and making improvements as a 
result.FDA’s new concepts for risk management amount to a “cultural shift” in the logic of drug approval and the FDA’s 
role. The key events that led to this change can be traced to a series of reports that highlighted the need for improved 
medical safety. In 1999, the IOM released a report entitled, “To Err is Human.” This report reviewed the nature and cause 
of medication errors, estimating that up to 98,000 people died each year due to these errors. In their assessment the IOM 
included both adverse drug reactions and human errors in drug administration. The report captured the attention of news 
reporters and the government. Headlines proclaimed alarm at the larger number of fatalities caused by medical errors. 
Consequently, there was a government-wide initiative started to develop methods and institute procedures to reduce 
medical errors.Statements made by FDA officials regarding some of these withdrawals suggested that the FDA no longer 
believed that passive oversight and re-labeling drugs with new warnings was sufficient. Furthermore, the FDA no longer 
believed that it was sufficient to identify safe conditions of use in the label and that healthcare professionals and patients 
had to comply with advocated directions of use for the drug to remain on the market. 
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Introduction 
 
There is also a misconception among some that the risk 
of, say, an adverse drug reaction in an individual is the 
same as its frequency in the population. However, it is 
possible for an individual, because of some 
susceptibility, to have a high risk of an adverse reaction 
that has a low frequency in the population. It is 
therefore best to separate notions of individual risk and 
population risk or frequency.As a summary of this new 
philosophy of risk management, the FDA staff issued a 
report to the Commissioner that highlighted processes 
for developing risk management systems and signaled 
new ideas for measuring and intervening to manage 
risks. 
 
_______________________ 
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US FDA (1999) Entitled, “Managing the Risks of 
Medical Products,” the FDA report borrowed heavily 
from risk management philosophies in other fields, 
such as environmental risk management and airline 
safety. It emphasized the process of developing risk 
management plans to control and manage drug safety. 
The risk management “revolution” at the FDA 
continues today. Under FDA regulations and the Food 
and Drug Administration’s Modernization Act, the 
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FDA may approve new drugs with new restrictions that 
are intended to assure safe use (Subpart H). These 
restrictions include limiting distribution to certain 
facilities or physicians with special training or 
experience or limiting distribution based on the 
condition of the performance of specified medical 
procedures. The regulations specify that the limitations 
must be commensurate with the specific safety 
concerns presented by the product. In addition, drugs 
continue to be approved with restrictions imposed by 
manufacturers seeking FDA approval.The risk 
management guidance contained several revisions that 
addressed concerns from industry. The draft guidance 
stated that for certain drugs that pose risk management 
concerns, there must be a Risk MAP that describes 
what risks are faces and how they will be handled. The 
plan must identify a series of “tools” or interventions 
used to control risk. These tools include a series of 
informational interventions (to health care providers, 
patients, or the public) and distribution controls that 
specific conditions or populations of patient or 
providers that limit the prescribing or dispensing of the 
medication. The tools must be pretested, and the plan 
must be evaluated periodically. 
 
Risk perception in drug therapy 
Understanding risk and how it is perceived is a crucial 
step toward creating programs and campaigns to raise 
awareness and make communities safe. In short, risk 
perception, or the ability to discern risk, is tied to risk 
tolerance, or an individual’s capacity to accept a certain 
amount of risk. Risk perceptions (including 
deliberative, affective, and experiential) are often 
targeted in health behavior change interventions, and 
recent meta-analytic evidence suggests that 
interventions that successfully engage and change risk 
perceptions produce subsequent increases in health 
behaviors. Health-related risk perceptions play an 
important role in motivating health behavior change. 
The late Bill Inman once wrote that ‘perception of risk 
is based less on statistics than on fear’, and there is 
little evidence that knowing what the actual risks are 
affects how the general public perceives and responds 
to them. The factors that lead to mistaken perceptions 
about the risks of using particular medicines have not 
been thoroughly explored, although some are known. 
For example, in a random sample of 500 consumers 
aged 18 years and over in Wisconsin, 14–54% thought 
that generic prescription drugs were riskier than brand-
name products, depending on the medical condition 
being treated, although financial incentives would have 
mitigated this view. There is also evidence that the 
more information consumers receive about the safety 
(or otherwise) of a medicine through direct-to-
consumer prescription drug advertising in the USA the 
riskier they are likely to think it is. Media reporting is 
also thought to be important [1-4]. 
 
Exhibit 1. Several key terms and concepts are used in risk assessment [5] 
 Hazard: A source of risk, such as a substance or action that can cause harm. 
 Exposure: Contact with a hazard in such a manner that effective transmission of the agent or harmful 
effects of the agent may occur. 
 Dose-response relationship: A relationship in which a change in amount, intensity, or duration of 
exposure is associated with a change in the risk of the outcome. 
 Risk: The combination of the likelihood (probability) and magnitude (severity) of an adverse event. 
 Uncertainty: An instance of limited knowledge, false assumption, or statistical variability that 
contributes to a statement of confidence in conclusions drawn from a risk assessment. 
 Risk management: The process of formulating and implementing a course of action to mitigate hazards 
determined by risk assessment to be important. 
 
The objective of therapeutic risk management 
Deployment of healthcare risk management has 
traditionally focused on the important role of patient 
safety and the reduction of medical errors that 
jeopardize an organization’s ability to achieve its 
mission and protect against financial liability. The 
hazards of not preparing for potential issues can have 
significant, long-term effects. Neglecting to have 
comprehensive risk management plans in place can 
compromise patient care, increase liability risks, and 
result in financial losses. Thus, potential risks have to 
be evaluated and measured in terms of their potential 
negative effects. Based on the risk assessment, an 
organization-specific management plan should be 
developed, implemented, and monitored. Given that 
each organization faces unique challenges, there is not 
a one-model-fits-all risk management solution. For 
example, the CDC recently published research that 
found that prolonged urinary catheter use is the leading 
risk factor for catheter-associated urinary tract 
infections. Based on this information, a risk 
management plan was implemented requiring 
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physicians to regularly evaluate the catheter. The end 
result was a decrease in patient risk. Challenges faced 
by administrators that should be addressed in a risk 
assessment plan include but are not limited to: 
 Patient safety 
 Mandatory federal regulations 
 Potential medical error 
 Existing and future policy 
 Legislation impacting the field of healthcare  
Risk Management can be Beneficial in the 
Following Contexts 
 ERM: Comprehensive risk management of the 
organization from top down including 
financial and business viability. 
 Patient care (Clinical) 
 Medical staff (Such as; credentialing, 
privileging, job description, employee 
insurance, trainings, medical coverage) 
 Non-medical staff (Such as; job description, 
training, medical coverage) 
 Financial (Budgeting, cost-benefit and cost-
effectiveness analysis, insurance coverage) 
 Managerial (Such as; organogram, Job 
descriptions, delegation of work) 
 Project risk management (Such as scope, time, 
cost, human resources, operational, procedural, 
technical, natural and political) 
 Facility Management and safety (Such as 
building safety, security of the facility, 
HAZMAT, emergencies internal and external, 
fire safety, medical equipment maintenance 
plan and maintenance plan for each of the 
utility system [6-10]. 
 
The Role of Healthcare Risk Managers: Risks to 
patients, staff, and organizations are prevalent in 
healthcare. Thus, it is necessary for an organization to 
have qualified healthcare risk managers to assess, 
develop, implement, and monitor risk management 
plans with the goal of minimizing exposure. There are 
many priorities to a healthcare organization, such as 
finance, safety and most importantly, patient care. 
Healthcare managers identify and evaluate risks as a 
means to reduce injury to patients, staff members, and 
visitors within an organization. Risk managers work 
proactively and reactively to either prevent incident or 
to minimize the damages following an event. Risk 
managers are trained to handle various issues in 
multiple settings. The duties a risk manager undertakes 
are ultimately determined by the specific organization. 
These professionals typically work in the following 
areas of medical administration: 
 Financing, insurance, and claims 
management 
 Event and incident management 
 Clinical research 
 Psychological and human healthcare 
 Emergency preparedness 
 
 
 
Figure 1. Role of Healthcare Risk Managers. As for any other type of medical error, development and 
widespread implementation of a total quality management system is the most effective strategy to minimize 
uncertainty in laboratory diagnostics. Pragmatically, this can be achieved using three complementary actions, 
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that are preventing adverse events (error prevention), making them visible (error detection), and mitigating their 
adverse consequences when they occur (error management). Owing to the volume and complexity of testing, a 
large number of errors still occur in laboratory diagnostics, especially in the extra-analytical phases of 
testing.There are already some noteworthy examples on how this can be translated into practice, such as the 
forthcoming introduction of a national EQA scheme for the preanalytical phase, or the development of a reliable 
program of quality control of the hemolysis index among different laboratories.(source: BiochemiaMedica 
Volume 20 June, Issue 2. Overview on patient safety in healthcare and laboratory diagnostics) 
 
A risk manager is often someone who has experience 
in handling risk-related issues in multiple settings. This 
individual should be able to identify and evaluate risks, 
which should then reduce the potential for injury to 
patients, staff members and visitors. For example, a 
registered nurse should notice if a bed rail should be 
modified. But detecting risks and making adjustments 
to reduce those risks goes much further. They include 
not filling expired prescriptions (prevents abuse), 
following up on missing test results (to increase 
consultations), tracking missed appointments (to 
manage risks), increased communication with patients 
(reduce improper taking of medication), and preventing 
falls and immobility. With the expanding role of 
healthcare technologies, increased cybersecurity 
concerns, the fast pace of medical science, and the 
industry’s ever-changing regulatory, legal, political, 
and reimbursement climate, healthcare risk 
management has become more complex over time. For 
these reasons, hospitals and other healthcare systems 
are expanding their risk management programs from 
ones that are primarily reactive and promote patient 
safety and prevent legal exposure, to ones that are 
increasingly proactive and view risk through the much 
broader lens of the entire healthcare ecosystem [7], 
[12,13]. 
 
Key Components of Performing Risk Management 
Risk management in health care is defined by clinical 
and administrative activities undertaken to identify, 
evaluate, and reduce the risk of injury to patients, staff, 
and visitors and the risk of loss to the organization 
itself.With the release of the risk management draft 
guidance the FDA has come to the conclusion that it is 
necessary to fully consider the risk management 
process for certain products considered for approval 
and for continuous marketing.  
Identify Risk: Since risk management involves 
managing uncertainty and new risk is constantly 
emerging, it is challenging to recognize all the threats a 
healthcare entity faces. However, through the use of 
data, institutional and industry knowledge, and by 
engaging everyone — patients, employees, 
administrators, and payers—healthcare risk managers 
can uncover threats and potentially compensatory 
events that otherwise would be hard to anticipate. 
Sources of risk identification 
 Discussions with department Chiefs, managers 
and staff 
 Patient Tracer Activity (Tracing the journey of a 
patient from admission till discharge) 
 Retrospective screening of patient records 
 Reports of accreditation bodies 
 Incident reporting system & Sentinel events 
 Healthcare Associated Infections (HAI) reports 
 Executive committee reports 
 Facility management & safety committee report 
 Patient complaints and satisfaction survey 
results 
 Specialized committee reports (such as 
Morbidity and mortality committee, medication 
management and use, infection control, blood 
utilization, facility management and safety 
committee) [6], [10]. 
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Figure 2. Population Management & Managed Care. Prescription Benefit Administration: The prescription 
administration service that reduces expenses associated with typical prescription benefit approaches which yields up 
to 20 percent in prescription plan savings. All necessary services are delivered and detailed transparent management 
reporting is provided. Medication Risk Management: Identifies and resolves Drug Therapy Problems (DTPs). 
Resolution of DTPs create a high quality of care and generate prescription and medical savings. (Source: Web 
Proxsys Rx) 
 
Risk Assessment: For most medicines the benefits are 
limited to a few indications and for an individual 
patient there is usually only a single benefit sought but 
the potential risks are multiple. Although at the time of 
approval knowledge about efficacy from small, short-
term clinical-trial populations is limited, far less is 
known about the drug’s risks. The evaluation of the 
benefit:risk ratio of a drug is essential throughout the 
whole life cycle of a drug. During the discovery phase, 
the analysis of the biological targets as well as medical 
chemistry will allow selection of lead molecules with 
the best BRA potential over hundreds of candidate 
molecules. The review of the benefits and the risks 
associated with a drug is called benefit: risk assessment 
(BRA), or benefit-risk balance, or benefit-risk ratio 
evaluation. BRA is basically an evaluation of two 
dimensions. The dimension of benefits is measured 
primarily in terms of therapeutic efficacy, i.e., the 
successful treatment of the condition for which the 
drug is indicated. There are other types of benefits, 
such as improvement of quality of life or 
pharmacoeconomic aspects, that are of interest in a 
period where the costs of medicine are closely 
scrutinized. The dimension of risks includes the safety 
profile observed in the form of the sum of all ADRs, 
but also includes the potential risk of unobserved 
ADRs anticipated on the basis of the mechanism of 
action [13-15]. 
Risk Quantification: In Europe, part of the mandate of 
the CHMP is to assess risks and benefits of authorized 
medicines on behalf of the EMEA. In 2007, the CHMP 
revised its guidance and included quantitative BRA in 
the regulatory agenda with the publication of a report 
examining the potential value of existing benefit–risk 
models and methods. Although no specific method was 
recommended, several BRA features were noted as 
being of value, including 1) all important benefits and 
medically serious risks are identified; and 2) the risks 
and benefits are weighted according to their relative 
importance and the strength of the evidence available. 
It was also decided that a comprehensive review of 
available quantitative methods for BRA relevant to the 
CHMP was required to explore further development of 
tailored methodologies. The EMEA created the 
ENCePP, which is in the process of developing an 
algorithm to articulate safety and benefit profiles for 
pharmaceutical products [16-18]. 
 
Development and Implementation of Risk 
Management Tools (eg, Risk Communication and 
Distribution and Behavioral Control Systems): Unsafe 
health care provision is a main cause of increased 
mortality rate amongst hospitalized patients all over the 
world. A system approach to medical error and its 
reduction is crucial that is defined by clinical and 
administrative activities undertaken to identify, 
evaluate, and reduce the risk of injury. WHO draft 
guideline and patient safety reports from different 
countries were reviewed for defining acceptable 
framework of risk management system.7 steps in the 
Risk Management process are establishment the 
context, identifying, analyzing, evaluating, and treating 
the risks, continuous monitoring and review, and 
communication and consultation. The literature reports 
on many different methods, strategies, and measures to 
introduce innovations, guidelines, best practices, or 
new procedures into clinical practice. Effective 
implementation of innovations seems to be more 
successful with strategies for implementation that are 
tailored to the specific goals, target group and setting 
[19,20]. 
 
Evaluation of the Effectiveness of tools and 
implementation of design modifications: The design 
and conduct of a range of experimental and non-
experimental quantitative designs are considered. Such 
study designs should usually be used in a context 
where they build on appropriate theoretical, qualitative 
and modelling work, particularly in the development of 
appropriate interventions. Evaluation informs the 
choice between alternative interventions or policies by 
identifying, estimating and, if possible, valuing the 
advantages and disadvantages of each. Campbell and 
colleagues have suggested that the evaluation of 
complex interventions should follow a sequential 
approach involving: 
 Development of the theoretical basis for an 
intervention; 
 Definition of components of the intervention 
(using modelling, simulation techniques or 
qualitative methods); 
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 Exploratory studies to develop further the 
intervention and plan a definitive evaluative 
study (using a variety of methods); 
 Definitive evaluative study (using quantitative 
evaluative methods, predominantly 
randomized designs) [21]. 
Overview of risk management around the world 
 ENCePP: In 10 years, the ENCePP has made 
a major contribution to the benefit‐risk 
evaluation of medicinal products in Europe 
and beyond by providing methodological 
recommendations complementing regulatory 
guidance on PASS. Perhaps most importantly, 
ENCePP has created a strong European 
community supporting methodological 
standards, transparency, and scientific 
independence in pharmaco-epidemiological 
research [22]. 
 ASHRM: ASHRM Annual Conference and 
Exhibition 2019 is going to take place in Oct 
13 - 16, 2019 (Baltimore, Maryland) with the 
mission statement “To provide health care risk 
managers with the resources, knowledge and 
support to strategically and broadly manage 
risk, reduce uncertainty, add value, and 
advance health and safety”.The identified 
risks were confirmed through a survey of risk 
managers from a range of global healthcare 
organizations during the ASHRM conference 
in 2017. In 2014, the ASHRM proposed risk 
domains for healthcare organizations, but 
again, risk events and scenarios are not 
described in detail. Other institutions, such as 
HIROC (Canada) and the NHS (England) 
have developed risk taxonomies that include 
clinical risks and enterprise risks.Finally, the 
risks are categorized by group using the 
ASHRM domains and COSO factors as 
guidelines [23-25]. 
 HIROC:HIROC, together with IRM Steering 
Committee comprised of risk management 
experts from various healthcare organizations, 
developed a web-based IRM Risk Register 
program in 2014.The 2016 top active risk 
themes were: patient care (30%); human 
resources (16%); financial (12%); leadership 
(11%); and information 
management/technology (10%). The top five 
active risks (by frequency) were: 
revenue/funding, regulatory/legislation; care 
communication; medication; and 
recruitment/retention of staff. The top five 
active risks (by rating) were: access to care, 
accreditation, adverse events, 
aging/maintenance of infrastructure, 
benefits/overtime [26]. 
 
Exhibit 2. 7 steps to IRM detailed by Borovoy, 2019 [27] 
 Exploration & Decision 
 Risk Register Sign-On 
 Ownership & Coordination 
 Risk Identification 
 Risk Register Validation 
 Sustainability & Review Process 
 Risk Register IRM Ongoing Development & Knowledge Sharing 
 
Healthcare Risk Management Plan 
Medicinal products are given authorization on the basis 
that, the   risk-benefit balance is judged to be positive 
for the target population   at the time of authorization. 
They appear to be safe and well tolerated  but safety in 
actual world is unclear as there are many limitations 
during clinical trials as medicinal products are studied 
in homogeneous  population in limited number in ideal 
conditions and with limitations  in  terms  of  age,  sex,  
race  and  ethnicity;  co-morbidity,  restricted  co- 
medication,  relatively  short  duration  of  study  and  
follow  up  and  the   marketed  drug  addresses  huge  
population  and  relatively  longtime   exposure. Thus, 
risk management plan plays a vital role in both pre and 
post approval of drug.The Risk Management Plan 
becomes the guiding document for how an organization 
strategically identifies, manages and mitigates risk. 
Hospital leadership and all department heads should be 
aware of and involved in the development and on-
going evaluation of the plan. Healthcare risk 
management plans communicate the purpose, scope, 
and objectives of the organization’s risk management 
protocol. They also define the roles and responsibilities 
of the risk manager and other staff involved in risk 
mitigation.Reviewing other studies is one way to 
develop risk management programs. Following the 
directives of governing organizations such as the 
Department of Health and Human Services, FDA and 
ASHRM ensures risk management compliance.  Using 
analysis results, risk managers can compare the 
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likelihood of different adverse events along with their 
impacts and rank potential risks in terms of severity. 
Plans for mitigating risks and handling them 
appropriately can then be developed. Risk management 
plans also undergo quality assessments so the 
interventions and actions proposed are addressed as 
real potential issues. Once a strategy is in place, it is 
monitored and modified as needed [6,7]. 
 
Exhibit 3. USAID detailed Risk Management Plan steps [28] 
 Step 1: Establish your context  
 Step 2: Identification of possible risks  
 Step 3: Assessment  
 Step 4: Potential risk treatments  
 Step 5: Create a risk management plan  
 Step 6: Implementation  
 Step 7:  Evaluate and review 
 
Effective Patient Care Practices 
The development and implementation of healthcare 
risk management programs are based on extensive 
ongoing research. Risk managers must stay up-to-date 
on relevant information in their organization because 
research results could prove contradictory to 
presumptions that would otherwise shape risk 
management practices. For example, one study 
published by JAMA Internal Medicine revealed that 
increasing the hours of sleep residents in teaching 
hospitals received actually compromised patient safety. 
The risk-management outcome was to ensure that 
strategies were in place to improve resident’s sleep 
schedules and reduce potential risks to patients.There 
are several challenges ahead for cultivating an effective 
and positive safety culture in healthcare organizations. 
To keep pace with international standards, healthcare 
managers must employ modern methods of 
management in order to overcome the challenges faced 
by the institutionalization of safety culture and to make 
a difference in the healthcare system.Safety experts 
have suggested the essential components for safety 
culture such as teamwork, leadership support, 
communication, and a just culture as well as a 
reporting and a learning culture[6], [29]. 
 
RMP safety specifications 
It summarizes on important identified risks, important 
potential risks, and missing information due to 
limitations of clinical trials. It helps to identify needs 
for data collection and helps in the construction of 
pharmacovigilance plan. The purpose of the safety 
specification in the RMP is to provide a synopsis of the 
safety profile of the medicinal product(s) in the 
intended population as described in the approved 
Summary of Products Characteristics (e.g. therapeutic 
indications, or contraindications), and should include 
what is known and areas of uncertainty about the 
medicinal product(s).In the safety specification of RMP, 
important identified or potential risks or missing 
information related to the use of the medicinal products 
in the target population and potential off-label use, 
should be discussed with reference to 
pharmacogenomics. The aspects indicated below 
should be considered [30]. 
 
Implementing Strategies for Patient Care 
In clinical studies, for example, IRBs monitor proposed 
research plans before they are implemented to ensure 
minimal risk to human subjects. Plans for risk 
management must cover patient-specific risks and be 
well documented; they must also be accessible to those 
working with patients.Research indicates that clinical 
guidelines are often not applied. The success of their 
implementation depends on the consideration of a 
variety of barriers and the use of adequate strategies to 
overcome them. It is estimated that about 30%–40% of 
patients receive treatment that is not based on scientific 
evidence, and 20%–25% receive treatments that are 
either not needed or potentially harmful. In addition, it 
is estimated that more than 50% of Americans do not 
take medications as they are prescribed, and 
approximately one third do not finish the course of 
therapy or skip doses. A successful introduction of 
guidelines involves the three steps of development, 
dissemination and implementation. Many patient risks 
can be reduced by adequately training physicians and 
staff, encouraging strong communication among staff-
members, providing counseling services for those 
working with patients, and conducting competency 
assessments.Other risks posed to patient safety can be 
mitigated using patient-specific risk management 
strategies such as: 
 Not filling expired prescriptions: Interpersonal 
communication is inherent in a majority of 
strategies seeking to engage health care 
professionals in the reduction and prevention of 
prescription drug abuse. Sending patients 
adequate notification of prescription expiration 
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will support communication between patients and 
physicians thus reducing potential prescription 
medication abuse. 
 Following up on missing test results: Failure to 
follow-up can lead to missed or delayed 
diagnoses which impact on patient care and can 
also have medico-legal implications for health 
services and health professionals.Patients who 
need to take additional medical tests following 
appointments may fail to do so, or the test results 
might get lost. Developing a plan to monitor 
receipt of test results guarantees the results are 
reviewed, so patients can then be consulted. 
 Tracking missed appointments: The problem 
with missed appointments is that continuity and 
effectiveness of healthcare delivery is 
compromised, appropriate monitoring of health 
status lapses, and the cost of health services 
might increase. Furthermore, some studies have 
shown a relationship between missed 
appointments and sub-optimal clinical outcomes 
among patients with chronic diseases 
Implementing a system to follow-up with patients 
who miss appointments but fail to reschedule is 
another proactive step in managing patient risks. 
 Communicating with patients: Evidence 
supports the importance of communication skills 
as a dimension of physician competence. Effort to 
enhance teaching of communication skills to 
medical trainees likely will require significant 
changes in instruction at undergraduate and 
graduate levels, as well as changes in assessing 
the developing communication skills of 
physicians. Patients may have limited 
understanding of information received from 
physicians. Having a strategy that checks the 
patient’s comprehension of information reduces 
the likelihood that the patient will misinterpret a 
physician’s orders or will improperly take 
medication.Successful communication should be 
uncomplicated, be specific, use some repetition, 
minimize jargon, check patient understanding. 
 Prevent falls and immobility: Although 
estimates of fall rates vary widely based on the 
location, age, and living arrangements of the 
elderly population, it is estimated that each year 
approximately 30% of community-dwelling 
individuals aged 65 and older, and 50% of those 
aged 85 and older will fall. Of those individuals 
who fall, 12% to 42% will have a fall-related 
injury. Making minor modifications to things like 
bed rails, bathtubs and toilets lacking grab bars, 
institutional lighting, and the conditions of the 
ground can significantly reduce the risks of such 
hazards. 
 Sufficient record retention - Keeping patient 
records on file for an extended period of time or 
indefinitely is useful for monitoring patient health, 
even when patients are not actively seeking care. 
Risk management protocol should also have plans 
in place for disposing of records in accordance 
with federal mandates.However, the widespread 
use of EHRs was delayed by high costs, data 
entry errors, poor initial physicians’ acceptance, 
and lack of any real incentive. The goal of 
replacing the entire paper chart with an electronic 
record was considered problematic due to the 
large initial costs resulting in the view that only 
key data should be computerized. As a result, the 
EHR would complement and not replace the 
paper record [31-37]. 
 
Exhibit 4. EU pharmacovigilance terminology [38] 
Term EMA definition 
Abuse  
Persistent or sporadic, intentional excessive use of medicinal products which is accompanied by 
harmful physical or psychological effects [DIR 2001/83/EC Art 1(16)] 
Medication 
error 
An unintended failure in the drug treatment process that leads to, or has the potential to lead to, 
harm to the patient 
Misuse  
Situations where a medicinal product is intentionally and inappropriately used not in accordance 
with the terms of the marketing authorization 
Occupational 
exposure  
For the purpose of reporting cases of suspected adverse reactions, an exposure to a medicinal 
product as a result of one’s professional or non-professional occupation. It does not include the 
exposure to one of the ingredients during the manufacturing process before the release as finished 
product 
Off-label use 
Situations where a medicinal product is intentionally used for a medical purpose not in 
accordance with the terms of the marketing authorization. Examples include the intentional use 
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Exhibit 4. EU pharmacovigilance terminology [38] 
Term EMA definition 
of a product in situations other than the ones described in the authorized product information, 
such as a different indication in terms of medical condition, a different group of patients (e.g. a 
different age group), a different route or method of administration or a different posology. The 
reference terms for off-label use are the terms of marketing authorization in the country where 
the product is used 
Overdose 
Administration of a quantity of a medicinal product given per administration or cumulatively 
which is above the maximum recommended dose according to the authorized product 
information. When applying this definition, clinical judgement should always be applied 
 
Pharmacovigilance planning 
An RMP serves as the central document in 
pharmacovigilance activities for an individual product, 
and contains three elements: (1) a safety specification 
describing the potential and identified risks as well as 
important missing information on adverse effects, (2) 
the pharmacovigilance plan, which describes proposals 
to acquire more data on possible risks, identified risks, 
and missing information, and (3) the risk minimization 
plan. RMPs are prepared and maintained by the 
pharmaceutical companies, but require approval by 
regulatory authorities, who may require companies to 
add new risks to the RMP or to initiate new risk 
minimization activities, including new studies for 
safety or efficacy. The newest EU legislation requires a 
summary of the RMP to be made public. In November 
2013, a team of European regulators initiated the 
SCOPE Joint Action; The SCOPE Joint Action was a 
public initiative co-ordinated by the MHRA in the UK. 
The SCOPE project evaluated then-current practices 
and developed tools to further improve the skills and 
capability in the pharmacovigilance network. The 
project was divided into eight separate work streams, 
five of which concentrated on pharmacovigilance 
topics—collecting information on suspected adverse 
drug reactions, identifying and managing safety issues 
(signals), communicating risk and assessing risk 
minimization measures, supported by effective quality 
management systems. The other three work streams 
focused on the functional aspects—coordination, 
communication and evaluation of the project. Through 
the project, SCOPE delivered guidance, training in key 
aspects of pharmacovigilance, and tools and templates 
to support best practice.2015 marks an important 
milestone in the maturity of medical biotechnology, 
with five or more biosimilar applications pending 
review by the US FDA. For the first time, a number of 
manufacturers will produce a series of highly similar 
but not identical medicines for the US market. It is 
important that the specific biologic or manufacturer is 
readily identified to ensure accurate tracing of AEs to 
the administered product. Increased use of barcodes on 
biologic drugs should improve tracing capabilities, as 
should implementation of the US DQSA/DSCSA, 
which outlines use of an interoperable electronic 
system to identify and trace prescription drugs in the 
USA. In the USA, post-approval safety signal detection 
is performed primarily using SRS and AS systems. 
SRSs (e.g., MedWatch and institution-based reporting) 
are considered passive surveillance methods, which 
rely on voluntary reports from physicians, pharmacists, 
other healthcare providers, and patients. AS methods 
include retrospective analysis of medical records at 
Sentinel-affiliated sites and drug or disease registries, 
as well as use of drug event monitoring (e.g., surveys 
of patients identified through electronic prescription 
data. Brand name reporting for biologics in SRSs can 
vary by the product class and jurisdiction. For example, 
84 % use of accurate brand names has been reported 
for insulins in the USA, whereas product-specific 
attribution of epoetins approached 99 % in the 
European Union (EU).In recent years, the scope and 
objectives of pharmacovigilance have expanded 
manifold due to changes in the global pharma 
environment, improved access to medicines, varied 
utilization of medicines and availability of newer, more 
powerful tools and databases for tracking and 
analyzing data; however, the discipline needs to evolve 
further to meet both public health system needs and 
consumer expectations.The recent efforts directed to 
enable the shift toward proactive PV and establishing 
global PV practices show that harmonized PV practices 
are required to meet the needs of the various 
stakeholders in PV (including health authorities, the 
pharmaceutical industry, health-care professionals, and 
consumers). In addition, harmonization would also 
promote the safer use of medicines and public health 
protection. The existing working practices of a 
particular region are directly correlated to the PV 
legislation that exists in that region. By defining the 
minimal requirements and practices, PV legislation 
thereby helping define how safety information about 
International Journal of Health and Clinical Research, 2019;2(2):16-33                e-ISSN: 2590-3241, p-ISSN: 2590-325X                         
                                                             
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Mohiuddin                    International Journal of Health and Clinical Research, 2019; 2(2):16-33 
www.ijhcr.com                              
        25 
 
medicinal products is reported to enable adequate 
benefit-risk assessment.While much progress has been 
made in PV practices, many deficiencies and issues 
still exist in the efforts to ensure safe medicine usage. It 
requires formal training for PV professionals and better 
communication tools. Safety information is 
communicated between different regulatory agencies, 
regulatory agencies and manufacturers, healthcare 
professionals and manufacturers, agencies and 
healthcare professionals, healthcare professionals and 
consumers. All parties in communication utilize 
different tools– from product labeling to adverse event 
reports [38-43]. 
 
Exhibit 5. Examples of adverse events reported to the TGA [42] 
Drug  Adverse event  
Sodium glucose co-transporter 2 inhibitors  Diabetic ketoacidosis (atypical presentation)  
Risperidone  Cerebrovascular events in patients with dementia  
Infliximab  Non-melanoma skin cancers (particular in psoriasis)  
Methotrexate  Hepatitis B reactivation  
Non-steroidal anti-inflammatory drugs (over-the-
counter doses used for prolonged periods)  
Cardiovascular events  
Diclofenac – hepatotoxicity  
Combined oral contraceptives and hormonal 
replacement therapy  
Potential link with inflammatory bowel disease  
Metoclopramide  Extrapyramidal events and cardiac conduction – new 
recommendations for prevention  
Pregabalin  Suicidal ideation  
Zolpidem  Next day impairment  
Duloxetine  Serotonin syndrome  
Rotavirus vaccine  Intussusception  
Denosumab  Severe hypocalcemia  
Proton pump inhibitors  Acute interstitial nephritis  
Clozapine  Constipation  
Exenatide  Pancreatitis  
 
Developing risk minimization plans/risk mitigation 
strategies 
An RMP documents the risk management system 
required to identify, characterize and minimize a 
product’s important risks. The TGA requires RMPs to 
be submitted for evaluation with certain higher-risk 
applications to enter a medicine or biological in the 
ARTG or to vary an ARTG entry. An RMP (or RMP 
update) will normally be expected with applications 
involving a significant change to an existing 
registration, such as a:significantly different population; 
pediatric indication; new dosage form or route of 
administration with inherently higher risk (e.g. oral 
tablets vs IV injection); new manufacturing process of 
a biotechnologically‐derived product or other 
significant change in indication. RMPs must be 
maintained throughout the lifecycle of the product and 
important updates submitted to the TGA for evaluation. 
A new RMP has to be submitted whenever TGA 
requests; whenever there is a significant (material) 
change to the RMP, including but not limited to:when 
the RMP is modified as a result of new information 
that may lead to a change to the benefit-risk profile; 
when an important (product vigilance or risk 
minimization) milestone is reached; or an activity is 
terminated, added, or substantially altered; when 
changes to the summary of ongoing safety concerns are 
made. This guidance: 
 Explains when you must submit an RMP with 
an application for registration, inclusion or 
variation in the ARTG 
 Describes what to include in an RMP and the 
required format for RMPs 
 Details special requirements for RMPs for 
biologicals 
 Outlines how the TGA evaluates RMPs 
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 Explains when to submit RMP updates after 
regulatory approval 
 Describes how the TGA monitors sponsor 
compliance with RMP commitments 
Similarly, Companies are required submit an RMP to 
the EMA when applying for a marketing authorization. 
To help applicants, EMA developed guidance on how 
to submit RMPs.RMPs include information on: 
 A medicine's safety profile; 
 How its risks will be prevented or minimized 
in patients; 
 Plans for studies and other activities to gain 
more knowledge about the safety and efficacy 
of the medicine; 
 Measuring the effectiveness of risk-
minimization measures. 
In the EU, companies must submit an RMP to the 
Agency at the time of application for a marketing 
authorization. For medicines that do not have an RMP, 
one may be required with any application involving a 
significant change to the marketing authorization.In 
addition, for nationally authorized medicinal products, 
any NCA in the EU can request an RMP whenever 
there is a concern about a risk affecting the benefit-risk 
balance of a medicine.RMPs are continually modified 
and updated throughout the lifetime of the medicine as 
new information becomes available. Companies need 
to submit an updated RMP: 
 At the request of EMA or an NCA; 
 Whenever the risk-management system is 
modified, especially as the result of new 
information being received that may lead to a 
significant change to the benefit-risk profile or 
as a result of an important pharmacovigilance 
or risk-minimization milestone being reached. 
When justified by risk, the competent authority can 
also specify a date for submission of the next RMP as a 
condition of the marketing authorization in exceptional 
cases.RMPs can only be submitted at the same time as 
the PSUR if the change in the RMP comes as a 
consequence of the PSUR [44,45]. 
 
Planning and implementation of Risk Minimization 
Measures (RMMs) 
An important element of risk management is the 
planning and implementation of RMMs and the 
evaluation of their effectiveness by process or outcome 
indicators.The effectiveness of RMMs can be evaluated 
by process and/or outcome indicators. Process 
indicators measure the extent to which a program was 
implemented, whether the execution was as planned, 
and the impact on knowledge and behavior of the target 
population. Outcome indicators provide an overall 
measure of the level of risk control achieved by RMM, 
for example, measuring rates of an adverse drug 
reaction or other safety‐related outcome. Evaluation of 
effectiveness of RMMs is important to manage the 
benefit‐risk balance of a medicinal product. 
Effectiveness of RMMs can be evaluated by using 
cross‐sectional survey studies and studies using 
secondary data sources.The EU PAS Register proves to 
be a valuable resource for identifying studies 
evaluating the effectiveness of RMMs in Europe.Half 
of the effectiveness indicators (process and/or outcome) 
were reported as successful [45]. 
 
Exhibit 6. A suggested set of strategic activities by the risk minimization function[46] 
 Leading strategic planning for risk minimization activities for the research portfolio as a whole as well 
as for individual products; 
 Executing or overseeing the execution of “best-in-class” risk minimization program design, 
implementation, and evaluation using knowledge from implementation science in health; 
 Conducting targeted research to develop improved risk minimization tools, methodologies, and 
evaluation approaches that support the company’s pipeline and marketed products’ portfolio; 
 Establishing a knowledge management system that: a) documents both internal and external “lessons 
learned” and the evolving risk minimization requirements and practices of regulatory authorities 
worldwide, and b) promulgates best practices in risk minimization science to internal teams; 
 Optimizing operational and cost efficiencies of risk minimization processes by standardizing processes 
where appropriate and leveraging preferred supplier and service provider arrangements; 
 Publishing risk minimization evaluations and research findings in order to advance the science in a “pre-
competitive” context; and 
 Achieving a sustained level of compliance globally with regard to risk minimization commitments 
through standard setting, monitoring, and ongoing technical support to company affiliate offices. 
 
Incorporating Risk Management and Quality 
Improvement into Organizational Planning 
Quality improvement involves a combined effort 
among health care staff and stakeholders to diagnose 
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and treat problems in the health care system. However, 
health care professionals often lack training in quality 
improvement methods, which makes it challenging to 
participate in improvement efforts. Quality 
improvement and the management of risks in health 
care should be part of both strategic and operational 
planning in every area and service of healthcare 
delivery, clinical and nonclinical. Risk management 
and quality improvement should be considered as an 
integrated approach when determining clinical practice, 
equipment design and procurement, capital 
development, information technology, contractor 
management, workplace health and safety, workforce 
management, and financial planning, and all other 
areas of operation.    
 
 
 
Figure 3: Risk management process overview (Source: AS/NZS ISO 31000 — 2009 Risk management — 
principles and guidelines) 
 
Healthcare organizations’ systems for risk management 
and quality improvement are reviewed within the 
NSQHS Standards under Standard 1: Governance for 
Safety and Quality in Health Service Organizations. In 
addition, NSQHS Standards 3-10 require organizations 
to undertake a risk assessment of their systems. For 
example, NSQHS Standard 4 requires a risk 
assessment of medication management systems. These 
risk assessments are managed by the associated 
governance committees with key risks also being 
represented on the organization-wide Risk Register. 
The same applies for quality plans. Organizations are 
required to submit a Quality Improvement Plan at each 
phase of their accreditation cycle and have a register of 
the organizational risks (Risk Register) available for 
ACHS surveyors at each onsite survey. For risk 
management and quality improvement programs to be 
most effective, the governing body and leadership team 
must demonstrate commitment to the processes and 
define their expectations for all stakeholders. In 
addition, the leadership team should ensure that there 
are sufficient resources to meet the requirements of the 
organization and systems to effectively mitigate, 
control and manage all risks, and that attention is 
focused on the core business of the organization – to 
care for and treat consumers / patients in a safe and 
high-quality clinical environment.Risk management 
and quality improvement systems are both directed to 
providing a structured framework for identification, 
analysis, treatment / corrective action, monitoring and 
review of risks, problems and/or opportunities. 
Communication and consultation with stakeholders are 
critical for these processes to work effectively.  
Continuous improvement and risk management are 
data driven. They depend on relevant information 
being provided to the executive, clinicians, managers 
and the governing body. The data and information 
provided should reflect the issues that are most 
significant to the organization, rather than just for the 
process of data and information collection itself. A 
range of tools that can be used for quality improvement 
also applies to analyzing risk issues [47-51].  
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Exhibit 7. The integrated risk management and quality improvement framework, documented in a plan 
that is provided to all staff members [47] 
Risk Management  Overlapping Functions  Quality Improvement 
• Accreditation compliance  
• Claims management  
• Consumer / patient relations 
and disclosure  
• Contract / policy review  
• Corporate and regulatory 
compliance  
• Mandatory event reporting  
• Risk identification, e.g. near 
miss and adverse event 
reporting  
• Risk control, e.g. loss 
prevention and loss reduction  
• Risk financing  
• Safety and security  
• Workers compensation  
• Accreditation issues  
• Analysis of adverse and 
sentinel events and trends  
• Board reports  
• Consumer / patient complaint 
handling  
• Consumer / patient education  
• Feedback to staff and 
healthcare providers   
• Proactive risk assessments  
• Public reporting of quality 
data  
• Provider credentialing 
• Root-cause analysis  
• Staff education and training  
• Strategic planning  
 
• Accreditation coordination  
• Audits / benchmarking / 
clinical indicators etc.  
• Best practice / clinical 
guidelines  
• Consumer / patient  
satisfaction  
• Improvement projects  
• Peer review  
• Provider performance and 
competency  
• Quality methodology  
• Quality of care reviews  
• Utilization / resource /case 
management  
 
Users of the health care system also possess unique 
knowledge and experiences that can inform quality 
improvement efforts and help design systems around 
the needs of the patient rather than the staff or  
 
 
organization. However, there is much debate over how 
to meaningfully involve patients and caregivers in 
quality improvement. Experience suggests that projects 
have a clear rationale and defined roles and 
responsibilities for patients and caregivers [48].  
 
Exhibit 8. Roles that patients and caregivers have played in quality improvement [48] 
 Identifying improvement opportunities 
 Creating a sense of urgency for change with storytelling 
 Acting as an outlet to solicit other patient experiences  
 Offering change ideas to redesign systems of care 
 Persuading health care providers that quality of care problems exists and need to be addressed 
 
A staff lead is assigned as the primary liaison for the 
group, with one or more assistants who have the dual 
responsibility of supporting the lead and learning the 
process so they may serve as a future lead. 
Qualifications for staff lead include service as an 
assistant staff lead on a prior guideline panel, 
experience conducting literature searches and using a 
citation database, and a basic understanding of study 
design, medical terminology, and levels of 
evidence.Guidelines meeting certain quality standards 
are included in the NGC database, an initiative of the 
Agency for Healthcare Research and Quality NGC 
inclusion criteria are:  
1. The clinical practice guideline contains 
systematically developed statements that include 
recommendations, strategies, or information that 
assists physicians and/or other health care 
practitioners and patients make decisions about 
appropriate health care for specific clinical 
circumstances. 
2. The clinical practice guideline was produced 
under the auspices of medical specialty 
associations; relevant professional societies, 
public or private organizations, government 
agencies at the federal, state, or local level; or 
health care organizations or plans. A clinical 
practice guideline developed and issued by an 
individual not officially sponsored or supported 
by one of the above types of organizations does 
not meet the inclusion criteria for NGC. 
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3. Corroborating documentation can be produced 
and verified that a systematic literature search 
and review of existing scientific evidence 
published in peer reviewed journals was 
performed during the guideline development. A 
guideline is not excluded from NGC if 
corroborating documentation can be produced 
and verified detailing specific gaps in scientific 
evidence for some of the guideline's 
recommendations. 
4. The full text guideline is available upon request 
in print or electronic format (for free or for a 
fee), in the English language. The guideline is 
current and the most recent version produced. 
Documented evidence can be produced or 
verified that the guideline was developed, 
reviewed, or revised within the last five years 
[51.52]. 
 
Exhibit 8. Five Basic Initiatives to Manage Risks [52] 
 Prevention: Proactive risk awareness and safety programs ensure that staff members are aware of 
potential risks and provide an understanding of how they can help protect patients, visitors and 
themselves. 
 Correction: Post-incident remedial actions minimize the impact of adverse events and help prevent 
future events.  
 Documentation:  Thorough and complete patient records, as well as comprehensive policies and 
procedures, facilitate better communication and stronger legal defense efforts when necessary.  
 Education: Creative and meaningful programs engage personnel in organizational risk-reduction 
initiatives, leading to a more empowered and effective staff.  
 Interdepartmental coordination: Creating a framework that encourages departments to work together 
fosters a safer organizational environment.  Together, these five elements allow 
 
Risk Management Processes and Strategies   
Risks should be considered using existing processes 
such as audits, data, trends, literature and risk 
assessment tools, as well as via planned reviews of 
issues with stakeholders through mechanisms such as 
brainstorming sessions. Tools used to screen and/or 
assess risks will vary depending on the risk being 
assessed. For example, consumer / patient risk 
screening and/or assessments such as falls risk or 
mobility assessment tools will be different from tools 
used to assess risks to achievement of strategic goals, 
or workplace safety risks. It is important that any tool 
used is validated by an expert internal source and/or 
agreed for use by the governing body. Examples of 
processes and strategies that assist with risk 
identification and management include: 
Clinical examples   
 Collection and effective use of clinical indicators  
 Morbidity and mortality reviews  
 Clinical audits  
 Adverse outcome screening and clinical incident 
reporting   
 Health record audits and clinical content reviews  
 Medical emergency reviews   
 Medication management strategies  
 Consumer / patient risk assessments (e.g. Falls, 
pressure areas, VTE)  
 Peer review and peer supervision  
 Effective use of complaints and feedback from 
consumers / patients and staff  
 Evidence, literature, research.   
 
Non-clinical examples  
 Collection and effective use of indicators relevant 
to the organization  
 Audit processes  
 Budget variance monitoring  
 Project activity reports   
 Purchasing and product evaluation   
 Fraud minimization schemes  
 WHS risk assessments and hazard identification  
 Lost time injury reports   
 Political change management strategies  
 Workplace safety strategies 
 Financial management strategies  
 Contingency and disaster planning  
 Redundancy in systems   
 Information technology and data entry system 
infrastructure and capabilities   
 Workforce planning   
 Credentialing and defining the scope of clinical 
practice for all clinicians  
 Recruitment and retention strategies  
 Education and mandatory training programs for 
staff  
 Staff performance review and development  
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 Equipment maintenance and replacement 
schedules  
 External contract reviews [47].  
 
Conclusion 
Several activities proposed by the RMPs do not appear 
to be adequate in dealing with the potential risks of 
drugs. Poor communication of risk to practitioners and 
to the public, and above all limited transparency for the 
total assessment of risk, seem to transform RMPs into a 
tool to reassure the public when inadequately evaluated 
drugs are granted premature marketing 
authorization.As discussed previously, once the FDA 
guidance is finalized, certain new drug applications 
will require a Risk MAP. The purpose of this program 
will be to propose, design, implement and evaluate a 
number of interventions intended to minimize the risks 
of using the drug. In similar fashion to a clinical 
development program, the Risk MAP will have a 
defined set of goals and objectives, developed 
specifically for the drug in question. Each Risk MAP 
must specify the overall goals of the program, (eg, 
specifying that no pregnant woman be prescribed a 
specific drug). For each goal, one or more objectives 
should be specified. These are intermediate steps 
necessary for achieving the overall goal, for example, 
specifying that all physicians must fully inform women 
patients about the risks of taking a drug if pregnant. 
Finally, a number of tools or interventions must be 
specified that will aid in obtaining the specified goals 
and objectives, for example, specifying that there will 
be a brochure and a video drafted for physicians to 
distribute to patients. Each of these tools should be 
justified and pretested to help assure that they will 
achieve their intended purpose(s). Risk management is 
a new and evolving discipline. It is difficult to argue 
that drugs should be provided to patients in a manner 
that minimizes potential hazards.The evaluation of 
safety of a pharmaceutical or biological product is 
carried out throughout the lifecycle of the compound. 
In order for a biopharmaceutical company to be 
prepared for post-approval safety monitoring, 
evaluation and mitigation, it must know what is 
required in terms of an RMP and a REMS and 
development of these tools must be started during drug 
development. Post-approval safety is not just a post-
approval consideration.  The FDA has advanced the 
public health by fostering greater attention over the 
discovery, quantification, and management of risks. 
However, any policy that results in new activities to 
control one set of hazards may result in creating new, 
unexpected, hazards. Thus, continuing to evaluate the 
hazards of drugs and the interventions intended to 
control these hazards, is essential to assure that the 
benefits of a Risk Minimization Program will, itself, 
outweigh its risks. 
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